주요 콘텐츠로 건너뛰기

귀하의 브라우저가 완벽하게 지원되지 않습니다. 옵션이 있는 경우 최신 버전으로 업그레이드하거나 Mozilla Firefox, Microsoft Edge, Google Chrome 또는 Safari 14 이상을 사용하세요. 가능하지 않거나 지원이 필요한 경우 피드백을 보내주세요.

이 새로운 경험에 대한 귀하의 의견에 감사드립니다.의견을 말씀해 주세요

Elsevier
엘스비어와 함께 출판

Optimize R&D outcomes in pharma & biotech with Elsevier data and tools

Elsevier helps R&D teams make confident drug development decisions. Gain critical insights from innovative AI workspaces and tools built on trusted evidence and domain expertise. R&D teams at 90%+ of the top pharma companies use Elsevier solutions.

Connect with our experts
Researchers looking toward a computer monitor

  • Elsevier와 함께 일하는 것은 즐거운 경험이었습니다… Elsevier는 저희의 독자적인 생물의학 지식 그래프에 통합할 데이터를 제공해 주었고, 데이터 과학과 약물 재창출 분야에서도 귀중한 전문성을 제공해 주고 있습니다.

    David Fajgenbaum

    EveryCure의 공동 창립자/대표

  • R&D 팀은 검증 가능한 과학적 근거에 빠르게 접근할 수 있어야 합니다… LeapSpace는 응답에 추적 가능한 인용을 제공함으로써 엄밀성과 투명성을 높여 줍니다.

    Victoria Ball

    Incyte의 글로벌 라이브러리 서비스 부디렉터

  • Reaxys를 통해 저희는 구조를 검색하고 다운로드하며, 이를 생물활성 데이터와 연결하고, 구조-활성 관계를 탐색할 수 있습니다… Reaxys는 중요한 인사이트를 놓치지 않을 것이라는 확신을 줍니다.

    Christine Richardson 박사

    Sygnature Discovery의 수석 과학자

  • Elsevier의 Embase에서 검색하면 입력한 키워드가 관련 Emtree 용어에 자동으로 매핑됩니다… 이는 효과적인 문헌 검색을 위한 필수 도구이며, 포괄적이고 정확한 결과를 보장합니다.

    Katharina Friedrich 의학박사

    규제 및 메디컬 라이팅 컨설턴트

AI-powered R&D solutions for pharma and biotech

Jan Erik Timmermann

지금 보기

|

Elsevier helps pharma and biotech teams bring innovations to market faster with end-to-end risk management. Our R&D solutions include biomedical and chemistry databases, curated datasets, predictive and analytical tools, and a research-grade AI workspace — LeapSpace. LeapSpace unifies key research workflows in one secure environment:

  • Explore complex scientific questions

  • Compare evidence and perspectives

  • Upload and analyze your own documents

  • Identify collaborators and topic experts

Designed to prioritize trust, privacy and security, LeapSpace enables faster discovery with confidence.

Talk to us about LeapSpace

Target identification and validation — Is our target druggable?

Science, people and tablet in lab for investigation

Elsevier curates, enriches and connects deep biological and translational data, so you can evaluate target-disease relevance with greater confidence early in discovery. Elsevier data for target identification and validation includes:

  • 18.6M biological relationships

  • Normalized data from ClinicalTrials.gov and public databases

  • Therapeutic area evidence from full-text literature (e.g., oncology, diabetes)

Explore biological, clinical, safety and competitive intelligence data — including early human trials — to identify risks sooner. Elsevier helps teams prioritize high-value targets and improve downstream success rates.

Talk to us about R&D solutions for target discovery

Hit identification to lead optimization — Are we advancing the most promising leads?

Cellular therapy

Elsevier connects chemistry data with biomedical evidence so you can progress confidently from hit identification through lead optimization. Elsevier data for hit identification to lead optimization includes:

  • Detailed experimental procedures for reactions, substances and bioactivities

  • 5.5M extracted safety and PK data lines

Surface ADME, off-target and liability signals to de-risk compounds before committing to a series. Explore structure-activity relationships and integrate biological insights to refine leads with greater precision. Elsevier helps teams prioritize the most promising series and avoid costly late-stage failures.

Talk to us about R&D solutions for hit to lead

Preclinical development — Have we surfaced translational risks?

Elsevier helps preclinical teams agree on research strategies with a higher probability of clinical translation by integrating high-quality chemistry, biology and safety evidence. Elsevier data for preclinical development includes:

  • Chemistry and biology data enriched with DMPK, ADME and toxicology research

Explore the chemical space linked to PK and liability trends. Connect targets and pathways to safety concerns, understand toxicity mechanisms and predict potential drug-drug interactions. Elsevier helps teams address safety and developability earlier — before costly experiments begin.

Talk to us about R&D solutions for preclinical teams

Clinical development — Do we have the evidence needed to de-risk clinical trials?

Female doctor giving instructions about prescription medicine to patient

Elsevier helps clinical development teams design stronger clinical trials with robust safety, feasibility and regulatory evidence. Elsevier data for clinical development includes:

  • Prior trial endpoints, dosing patterns, comparator choices, safety outcomes and translational research

Anticipate exposure- and dose-related risks to reduce costly early-phase rework. Monitor emerging risks across compound classes and competitors to translate preclinical insights into clinical strategies with greater clarity. Elsevier helps teams strengthen trial design and make confident, defensible decisions.

Talk to us about R&D solutions for clinical development

Regulatory approval and post-market surveillance — Are we ahead of safety risks?

View of Earth from space

Elsevier helps pharmacovigilance, regulatory and safety teams detect safety signals earlier and make defensible decisions with regulator-ready evidence. Elsevier data for regulatory approval and post-market surveillance includes:

  • Richly indexed global biomedical literature and regulatory documents for precise, reproducible evidence

Conduct comprehensive literature reviews using full-text journal articles, conference abstracts and grey literature. Monitor adverse events, emerging safety signals and real-world performance with traceable, audit-ready citations. Elsevier helps you detect, assess and validate safety signals with greater speed and rigor.

Talk to us about R&D solutions for safety and regulatory teams

Elsevier helps pharma and biotech impact-makers succeed